Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
20-valent pneumococcal conjugate vaccine in infants
NCT05512819Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of Prevnar 20 in pneumococcal disease, sponsored by Pfizer. Started Sep 2022; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05512819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512819.